科研之友
微信
新浪微博
Facebook
分享链接
摘要
Nemonoxacin (Taigexyn (R)), a non-fluorinated quinolone antibacterial agent, is under development with TaiGen Biotechnology for the oral and intravenous treatment of community-acquired pneumonia (CAP) and the oral treatment of diabetic foot ulcer infections and skin and soft tissue infections. Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults. This article summarizes the milestones in the development of nemonoxacin leading to this first approval for the treatment of CAP.
- 出版日期2014-8
